Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $145

Benzinga Newsdesk www.benzinga.com Positive 85.2%

Neg 0% Neu 0% Pos 85.2%

Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $140 to $145.